To kick things off...Some of you might have missed my post on the RB board about my conversation with Dr. Schwartzentruber at Goshen. I posted it while a lot of the usual crap was going on, so it might have gotten lost in the mud. If you recall, he is the Goshen doc who is mentioned on the BOCX-Goshen P.R.
Anyways, first of all I asked him how the relationship formed. He said he contacted BOCX, rather than vice versa, and said that it was on the basis of data they had published but declined to give any more specifics.
Then I asked him what Goshen's focus would be. He said unequivocally imaging. He said that since Abbott is involved with the diagnostics, they feel that they could be most helpful/pioneering with regard to the imaging aspect. He also said they have a great deal of expertise with regard to tumor imaging. (There goes the theory that Abbott was behind Goshen, possibly to use them as a clinical trial site)
I asked him if they were planning on organizing clinical trials and publishing the results, and he said "that's the whole point of what we do."
I asked him if the data was too good to be true, and he said it's definitely remarkable data that has had all sorts of independant verification at this point but could not be considered "conclusive" yet (as BOCX themselves have said). He said "that's what we're trying to find out."
I asked him about timelines and he laughed and said "that's a good question," which says to me that they are a research institution at the end of the day -- not a corporation like Abbott -- and probably don't have a streamlined process for doing this sort of thing as abbott seems to have.
Hope that's helpful, guys.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.
